Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | CP-506 |
| Trade Name | |
| Synonyms | CP 506|CP506 |
| Drug Descriptions |
CP-506 is a DNA alkylating hypoxia-activated prodrug, which potentially induces cytotoxicity in tumor cells under hypoxic conditions and inhibits tumor growth (PMID: 34625504). |
| DrugClasses | Chemotherapy - Alkylating 18 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Atezolizumab + CP-506 | Atezolizumab CP-506 | 0 | 1 |
| Avelumab + CP-506 | Avelumab CP-506 | 0 | 1 |
| Carboplatin + CP-506 | CP-506 Carboplatin | 0 | 1 |
| Cemiplimab + CP-506 | CP-506 Cemiplimab | 0 | 1 |
| CP-506 | CP-506 | 0 | 1 |
| CP-506 + Durvalumab | CP-506 Durvalumab | 0 | 1 |
| CP-506 + Ipilimumab | CP-506 Ipilimumab | 0 | 1 |
| CP-506 + Nivolumab | CP-506 Nivolumab | 0 | 1 |
| CP-506 + Pembrolizumab | CP-506 Pembrolizumab | 0 | 1 |